Biotronik said today it launched the “ultra-high” energy Inventra HF-T, touting it as the 1st and only implantable cardioverter defibrillator available to deliver 42 joules in the 1st shock.
The new addition to Biotronik’s line includes the company’s DX system, which offers dual-chamber diagnostics with a single specialized defibrillator lead.
“For an increasing number of patients – specifically those with larger cardiac anatomy and lower ejection fraction – a shock that is higher than the standard 36-37 J may be needed to convert irregular arrhythmia. The sooner an effective shock can be delivered, the likelihood of survival increases for these patients. For such patients, a CRT-D that delivers ultra-high energy on the first shock has a higher chance of converting the irregular arrhythmia. With the availability of Inventra HF-T, more heart failure patients will be able to receive 42 J energy delivered upon the first shock and, hence, receive life-saving therapy,” Dr. Mark Mascarenhas of Neptune, New Jersey’s Jersey Shore University Medical Center said in a press release.
“We invest significantly in research and development focused on advancements that improve patient lives and reduce risks, for the patient and the provider. Within the industry, Biotronik stands out for its commitment to the principle of vertical integration. This means we design, develop and manufacture all critical components in house. The Inventra HF-T QP is the latest example of our dedication to producing devices of the highest quality and safety, as it is uniquely able to provide 42 J of energy at first shock without compromising battery longevity. I am proud that for the first time, heart failure ICD patients in the US can receive ultra-high energy therapy when needed,” prez Marlou Janssen said in a prepared statement.
In September, Biotronik released data from studies of its Pulsar-18 bare metal self-expanding stent and Passeo-18 Lux drug-coated ballon, touting high rates or primary patency and freedom from target lesion revascularization in both stand-alone and combined therapy procedures in lower-limb interventions.
The Berlin-based company presented 12-month interim results from its Bioflex Peace registry study of its Pulsar-18, reporting a primary patency rate of 75% and 93.1% rate of freedom from TLR. Preliminary data from the 1st 200 patients in the company’s Biolux P-III, all-corners registry of its Passeo-18 DCB indicated a 94% rate of freedom from clinically-driven TLR at 94%, Biotronik said.
